Two trials with Cyberknife SBRT (Accuray) for Prostate Cancer published
Two studies confirm with a much larger patient population and longer follow-up that CyberKnife stereotactic body radiotherapy (SBRT), from Accuray, is an effective method for treating Prostate Cancer. One study in more than one thousand patients with organ-confined prostate cancer, relapse-free survival rates were comparable to other established treatments at both three- and five-year intervals post-treatment. Additionally, for the 135 patients with at least 5 years follow-up, disease-free survival was 99% for low-risk and 93% for intermediate-risk patients.
The second demonstrated that CyberKnife SBRT was a well-tolerated treatment that allowed patients to return to their pre-treatment health-related quality of life (QOL). Sexual QOL declined in the first nine months in a manner that was no worse than that seen with other modern approaches to radiation therapy and observed in other studies. Overall the QOL outcomes compared favorably to surgery and other kinds of radiotherapy.
See: "Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials." King CR et al. Radiother Oncol. 2013 Sep 20. pii: S0167-8140(13)00430-1 and "Health-Related Quality of Life After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Results From a Multi-institutional Consortium of Prospective Trials" King CR et al. International Journal of Radiation Oncology 10 October 2013 DOI: 10.1016/j.ijrobp.2013.08.019
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins